Compare Global X Autonomous & Electric Vehicles (DRIV) vs Humana Inc (HUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Autonomous & Electric Vehicles vs Humana Inc — how do they compare? Global X Autonomous & Electric Vehicles trades at $32.79 (market cap $356.37M), while Humana Inc trades at $431.03 (market cap $46.49B). The key difference: Humana Inc is far larger — about 130.5× Global X Autonomous & Electric Vehicles's market cap, and Humana Inc pays a 0.91% dividend while Global X Autonomous & Electric Vehicles pays none. Which is the better fit depends on your goals — on Pluang, investors hold Global X Autonomous & Electric Vehicles for 40 Days and Humana Inc for 51 Days on average.
| DRIV | HUM | |
|---|---|---|
Market Cap | $356.37M | $46.49B |
Volume | 22,397 | 2,567,704 |
Sector | Sector/Thematic | Health |
52-Week High | $42.53 | $409.85 |
52-Week Low | $27.58 | $163.67 |
Typical Hold Time | 40 Days | 51 Days |
Enterprise Value | — | $53.84B |
Dividend Yield | — | 0.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DRIV trades at $32.79, down 1.72% today amid mixed technical signals. The stock shows a bullish overall technical signal but bearish moving averages, with neutral oscillators suggesting consolidation. Recent automotive sector news highlights hybrid vehicle momentum and China's EV ambitions, potentially impacting this automotive-focused investment.
Investment outlook remains cautious pending fundamental data verification. Key opportunities include exposure to automotive innovation trends, while risks involve sector volatility and reliance on unverified financial metrics. The technical setup suggests near-term consolidation around current levels.
Humana (HUM) trades at $431.03, up 8.71% over the past day, reflecting strong momentum following a Barclays upgrade and positive earnings beats. The stock exhibits a bullish technical trend, with support at $378 and resistance at $394. Revenue has grown steadily from $92.9B in 2022 to $129.7B in 2025, though net income margins have compressed to 0.88%. Analyst consensus is a Buy with a $457.05 price target, and recent news highlights corporate initiatives and institutional investments.
The outlook for HUM is cautiously optimistic, driven by revenue growth and analyst support, but risks include margin pressure and regulatory scrutiny. Investment opportunity lies in execution of Medicare Advantage strategies, while key risks involve competitive pressures and potential fiduciary concerns highlighted in recent shareholder notices.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Autonomous & Electric Vehicles
DRIV invests in companies involved in autonomous driving and electric vehicle production. It tracks the Solactive Autonomous & Electric Vehicles Index, focusing on software and hardware leaders like Tesla, NVIDIA, and Microsoft.
Read more on DRIV →About Humana Inc
Humana is one of the largest private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from individual and group Medicare Advantage, Medicaid, and the military's Tricare program. The firm is also a leader in stand-alone prescription drug plans for seniors enrolled in traditional fee-for-service Medicare. Humana offers employer-based plans primarily for small businesses along with specialty insurance offerings such as dental, vision, and life. Beyond medical insurance, the company provides other healthcare services, including primary-care services, at-home services, and pharmacy benefit management.
Read more on HUM →
